• 1
    Parfitt A. The physiologic and clinical significance of bone histomorphometric data. In: ReckerR (ed.). Bone Histomorphometry. Techniques and Interpretation. CRC Press Inc., Boca Raton, CA 1983; 143223.
  • 2
    Rodan GA. The development and function of the skeleton and bone metastases. Cancer Suppl 2003; 3: 72632.
  • 3
    Takahashi N, Udagawa N, Takami M. Cells of bone: osteoclast generation. In: BilezikianJP, RaiszLG, RodanGA (eds). Principles of Bone Biology, 2nd edn. Academic Press, San Diego, CA 2002; 10926.
  • 4
    Hofbauer LC, Gori F, Riggs BL et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblast linage cells. Endocrinology 1999; 1999: 43829.
  • 5
    Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle W, Lacey D, Riggs B. Role of RANK ligand in mediating increased bone resorption in early post-menopausal women. J Clin Invest 2003; 111: 122130.
  • 6
    Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999; 140: 436770.
  • 7
    Saika M, Inoue D, Kido S, Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 2001; 142: 220512.
  • 8
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by new members of the tumour necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 34557.
  • 9
    Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000; 289: 15014.
  • 10
    Nakashima K, Zhou X, Kunkel G et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108: 1729.
  • 11
    Spelsberg TC, Subramaniam M, Riggs BL, Khosla S. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol 1999; 13: 81928.
  • 12
    Sluijmer AV, Heineman MJ, De Jong FH, Evers JL. Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab 1995; 80: 21637.
  • 13
    Cummings SR, Browner WS, Bauer D et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998; 339: 7338.
  • 14
    Khosla S, Spelsberg TC, Riggs BL. Sex steroid effects on bone metabolism. In: SeibelM, RobinsS, BilezikianJP (eds). Dynamics of Bone and Cartilage Metabolism. Academic Press, San Diego, CA 1999; 23345.
  • 15
    Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 113741.
  • 16
    Theriault RL. Pathophysiology and implications of cancer treatment-induced bone loss. Oncology (Williston Park) 2004; 18: 1115.
  • 17
    Eriksen EF, Colvard DS, Berg NJ et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988; 241: 846.
  • 18
    Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 1991; 88: 661317.
  • 19
    Lower EE, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med 1999; 8: 94954.
  • 20
    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 171829.
  • 21
    Nabholtz N, Pienkowski T, Mackey J et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5_fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: interim analysis of teh BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21: Abstract 141.
  • 22
    Goodwin PJ, Ennis M, Pritchard KI et al. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 1999; 17: 1209.
  • 23
    Reichman BS, Green KB. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects. J Natl Cancer Inst Monogr 1994; 16: 1259.
  • 24
    Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19: 330611.
  • 25
    Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15: 13417.
  • 26
    Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001; 37: 23738.
  • 27
    Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15: 95562.
  • 28
    Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 7884.
  • 29
    Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006; 24: 67580.
  • 30
    Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20: 7517.
  • 31
    Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 602.
  • 32
    Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 274757.
  • 33
    Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793802.
  • 34
    Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 108192.
  • 35
    Howell A. Effect of anastrozole on bone mineral density: 2 year results of the anastrazole, tamoxifen, alone or in combination (ATAC) trial. SABCS 2003;Abstract 129.
  • 36
    Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 118996.
  • 37
    Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67: 7016.
  • 38
    Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 121922.
  • 39
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 1816.
  • 40
    Berruti A, Dogliotti L, Terrone C et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 23617.
  • 41
    Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995; 57: 979.
  • 42
    Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897903.
  • 43
    Baron JA, Barrett J, Malenka D et al. Racial differences in fracture risk. Epidemiology 1994; 5: 427.
  • 44
    Duan Y, Wang XF, Evans A, Seeman E. Structural and biomechanical basis of racial and sex differences in vertebral fragility in Chinese and Caucasians. Bone 2005; 36: 98798.
  • 45
    Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995; 17: 505S11S.
  • 46
    Flicker L, Mead K, MacInnis RJ et al. Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc 2003; 51: 15338.
  • 47
    Sambrook PN, Cameron ID, Cumming RG et al. Vitamin D deficiency is common in frail institutionalised older people in northern Sydney. Med J Aust 2002; 176: 560.
  • 48
    Pasco JA, Henry MJ, Nicholson GC, Sanders KM, Kotowicz MA. Vitamin D status of women in the Geelong Osteoporosis Study: association with diet and casual exposure to sunlight. Med J Aust 2001; 175: 4015.
  • 49
    Working Group of the Australian and New Zealand Bone and Mineral Society, Endocrine Society of Australia and Osteoporosis Australia. Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med J Aust 2005; 182: 2815.
  • 50
    Bruanwald E, Fauci AS, Kasper DL et al, (eds). Harrison’s Principles of Internal Medicine, 15th edn. McGraw-Hill, New York 2001.
  • 51
    Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 6706.
  • 52
    Diel IJ. Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol 2001; 28: 7580.
  • 53
    Russell RG, Bisaz S, Fleisch H et al. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet 1970; 2: 899902.
  • 54
    Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973; 11: 26980.
  • 55
    Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983; 35: 8799.
  • 56
    Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA. Antiresorptive dose–response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 1989; 15: 38996.
  • 57
    Rogers MJ, Gordon S, Benford HL et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 296178.
  • 58
    Brown J, Lester J, Ellis S et al. Can an annual infusion of zoledronic acid protect against cancer-treatment induced bone loss? J Clin Oncol (Meeting Abstracts) 2005; 23: Abstract 8023.
  • 59
    Fuleihan G, Salamoun M, Mourad YA et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90: 320914.
  • 60
    Gnant M, Jakesz R, Mlineritsch B et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrazole versus goserelin plus tamoxifen – bone density subprotocol results of a randomized multicentre trial (ABSCG-12). SABCS 2004;Abstract 6.
  • 61
    Brufsky W, Harker W, Beck J et al. Zoledronic acid effectively inhibits cancer treatment-induced bone loss in post-menopausal women with early breast cancer receiving adjuvant letrozole: 12 month BMD results of the Z-FAST trial. J Clin Oncol (Meeting Abstracts) 2005; 23: Abstract 533.
  • 62
    Bundred N. Zolendronic acid in the prevention of cancer treatment-induced bone loss on postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST Trial). 5th European Breast Cancer Conference, 21–25 March, Nice, France, 2006.
  • 63
    Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 15616.
  • 64
    Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 94855.
  • 65
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 200812.
  • 66
    Agnusdei D, Iori N. Raloxifene: results from the MORE study. J Musculoskelet Neuronal Interact 2000; 1: 12732.
  • 67
    Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 404257.
  • 68
    Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 21319.